Daiichi Sankyo and AstraZeneca's ENHERTU also improved progression-free survival by 22 months versus T-DM1 in patients previously treated with HER2 directed therapy in the DESTINY-Breast03 phase
LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) Wednesday announced that ENHERTU, a HER2-directed antibody-drug conjugate or ADC, achieved statistically significant overall survival, reducing the risk
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2. These patients with HER2 low status may now be eligible for a targeted treatment, which could significantly
In early August, the U.S. Food and Drug Administration approved of a new treatment option called Enhertu for unresectable or metastatic HER2-low breast cancer. This is the first targeted therapy